Skip to main content
Premium Trial:

Request an Annual Quote

Celera Losses and Revenues Fall in Third Quarter

Celera Genomics cut its losses by almost half but also saw its revenues fall by a third as the company issued its third quarter 2003 financial results today.

 

The Rockville, Md.-based firm reported a net loss of $26.7 million for the quarter, compared to a net loss of $49.5 million for the year ago quarter. The company had revenues of $20.3 million compared to $30.5 million for the year-ago period and cited its decision not to pursue additional sequencing service business as a primary reason for the drop.

 

The company took a $15.1 million non-cash charge for its investment in Discovery Partners International, based on the impairment of goodwill and long-term assets, a charge that amounted to $0.13 a share of Celera’s third-quarter net loss of $0.37 a share.

 

The company’s third-quarter research and development expenses were $27 million, compared to $37.6 million in the third quarter of 2002, based, the company said, on the wind down of the research phase of the Applera Genomics Initiative and programs eliminated in a restructuring in June.

 

The firsm reported cash and short-term investments of $824 million.
The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.